Osimertinib plus chemotherapy improves survival in EGFR-mutated lung cancer
Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed EGFR-mutated advanced non-small cell lung cancer…